Synonyms: Margenza® | margetuximab-cmkb | MGAH-22
margetuximab is an approved drug (FDA (2020))
Compound class:
Antibody
Comment: Margetuximab is a chimeric monoclonal antibody targeting epidermal growth factor receptor 2 (ERBB2).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence search of patented sequences reveals a 100% match between the heavy chain variable domain of margetuximab and SEQ ID NO: 13 from patent US8802093 B2, and antibody clone ch4D5-FcMT3 [2]. Although the patent describes performing Biacore assays to determine antibody-target (ERBB2) affinity, a KD value is not provided. |
Classification | |
Compound class | Antibody |
Approved drug? | Yes (FDA (2020)) |
International Nonproprietary Names | |
INN number | INN |
9799 | margetuximab |
Synonyms |
Margenza® | margetuximab-cmkb | MGAH-22 |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 473 |
Other databases | |
GtoPdb PubChem SID | 252166886 |
Search PubMed clinical trials | margetuximab |
Search PubMed titles | margetuximab |
Search PubMed titles/abstracts | margetuximab |